-

$undefined

N/A

(N/A)

Leap Therapeutics NASDAQ:LPTX Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

Location: 47 Thorndike St Ste B1-1, Massachusetts, 02141-1799, US | Website: www.leaptx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-31.54M

Cash

47.25M

Avg Qtr Burn

-15.07M

Short % of Float

11.99%

Insider Ownership

3.24%

Institutional Own.

48.63%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Sirexatamab (DKN-01) + Pembrolizumab Details Cancer, Endometrial cancer Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirexatamab (DKN-01) + Bevacizumab and Chemotherapy Details Cancer, Advanced microsatellite stable colorectal cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirexatamab (DKN-01) +/- Paclitaxel Details Cancer, Carcinosarcoma, Ovarian cancer, Endometrial cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FL-301 Details Cancer, Pancreatic cancer, Gastric cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirexatamab (DKN-01) +/- Docetaxel Details Prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirexatamab (DKN-01) + Tislelizumab +/- CAPOX Details Gastroesophageal junction tumors, Cancer, Gastric cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.